Skip to main content
LIFECOME BIOCHEMISTRY CO., LTD. logo

LIFECOME BIOCHEMISTRY CO., LTD. — Investor Relations & Filings

Ticker · 002868 ISIN · CNE100002QH2 LEI · 65560089EP03NANEN790 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,742 across all filing types
Latest filing 2025-11-26 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 002868

About LIFECOME BIOCHEMISTRY CO., LTD.

https://www.pclifecome.com

Lifecome Biochemistry Co., Ltd. focuses on the research, development, and large-scale production of fermentation-based veterinary pharmaceuticals and feed additives. The company’s core product portfolio includes Bacitracin Zinc, Bacitracin Methylene Disalicylate (BMD), and Colistin Sulfate, available in both active pharmaceutical ingredient (API) and premix forms. These biochemical products are primarily utilized in the livestock and poultry sectors to manage enteric health and improve feed efficiency. The organization operates advanced fermentation and purification facilities, maintaining compliance with international Good Manufacturing Practices (GMP) and various global regulatory standards. By leveraging specialized biotechnological processes, the company provides high-purity solutions aimed at enhancing animal nutrition and disease prevention across international markets.

Recent filings

Filing Released Lang Actions
关于拟续聘2025年度审计机构的公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the proposed reappointment of the audit firm (立信会计师事务所) for the fiscal year 2025. It details the audit firm's background, personnel, integrity records, and the board's approval process for the reappointment. There is no actual audit report or financial statements included, only information about the audit firm and the reappointment process. The document length is 4060 characters, which is relatively short and consistent with an announcement rather than a full audit report. Therefore, this document is best classified as an Audit Report / Information announcement (AR), specifically about the audit firm appointment, rather than the audit report itself or an annual report. FY 2025
2025-11-26 Chinese
第五届董事会第二十六次（临时）会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of a board meeting resolution regarding the proposal to reappoint the audit firm for the 2025 fiscal year. It includes details about the meeting, voting results, and references a separate announcement for the audit firm reappointment. The document does not contain financial statements or audit reports itself but is a formal board/management announcement about a decision. Therefore, it fits best under Board/Management Information (MANG). The document length is short and it is not a report or audit report itself, but a meeting resolution announcement.
2025-11-26 Chinese
关于出售浦城县农村信用合作联社部分股权完成工商变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the completion of a business registration change following the sale of a portion of equity in a rural credit cooperative. It references prior announcements and shareholder meeting resolutions about the sale. The content is about the progress and completion of a transaction and related administrative updates, not a financial report or detailed financial data. It is a regulatory announcement about a corporate action (equity sale and registration update). This fits best under Regulatory Filings (RNS) as it is a general regulatory announcement and does not fit other more specific categories like Capital/Financing Update or Share Issue/Capital Change, since it is about completion of registration rather than new financing or share issuance.
2025-11-25 Chinese
浙商证券股份有限公司关于绿康生化股份有限公司重大资产出售暨关联交易实施情况之独立财务顾问核查意见
Audit Report / Information Classification · 95% confidence The document is titled as an "Independent Financial Advisor's Verification Opinion" regarding a major asset sale and related party transaction by a listed company. It references compliance with laws such as the Company Law, Securities Law, and the Measures for the Administration of Major Asset Restructurings of Listed Companies. The content includes detailed descriptions of the transaction, asset valuation, approval processes, implementation status, and compliance with disclosure obligations. It is a standalone report issued by an independent financial advisor verifying the implementation of a major asset sale and related party transaction, rather than the full annual report or audit report. The document length is about 8980 characters, which is substantial and contains detailed substantive content, not just an announcement or certification. This fits the definition of an Audit Report / Information (AR) as it is a standalone report related to a major asset restructuring and includes verification and compliance opinions by an independent financial advisor. Therefore, the correct classification is AR with high confidence. FY 2024
2025-11-25 Chinese
绿康生化股份有限公司重大资产出售暨关联交易实施情况报告书
Capital/Financing Update Classification · 95% confidence The document is titled '重大资产出售暨关联交易实施情况报告书' which translates to 'Implementation Report on Major Asset Sale and Related Party Transaction'. It details the implementation status of a major asset sale transaction by the company, including transaction overview, asset valuation, approval processes, execution status, and opinions from independent financial and legal advisors. The document includes detailed descriptions of the transaction, approvals, asset handover, and compliance with regulations. It is not an announcement of a report publication but a substantive report on the transaction implementation. This type of document fits the category of a detailed report on a major asset sale and related party transaction implementation, which aligns with the category of Capital/Financing Update (CAP) as it involves significant changes in company assets and capital structure through asset disposal and related party transactions. The document is over 10,000 characters, indicating it is a full report rather than a brief announcement. Therefore, the appropriate classification is CAP with high confidence.
2025-11-25 Chinese
北京市竞天公诚律师事务所关于绿康生化股份有限公司重大资产出售暨关联交易实施情况的法律意见书
Legal Proceedings Report Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the implementation of a major asset sale and related party transaction by a listed company. It details the transaction scheme, approvals, implementation status, and legal compliance. The document is not a financial report, earnings release, or management discussion but a standalone legal opinion on a specific transaction. It does not contain financial statements or quarterly/yearly performance data. It is not a report publication announcement since it is substantive and lengthy (over 8,000 characters). The content fits best under Legal Proceedings Report (LTR) as it relates to legal opinions on a significant corporate transaction and compliance matters.
2025-11-25 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.